Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

The goal of this Phase I/II trial is to assess the safety and efficacy of administering durvalumab concurrent with weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide (ddAC) neoadjuvant therapy for stages I–III triple-negative breast cancer. The primary endpoint is pathologic complete...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:NPJ Breast Cancer
Autori principali: Foldi, Julia, Silber, Andrea, Reisenbichler, Emily, Singh, Kamaljeet, Fischbach, Neal, Persico, Justin, Adelson, Kerin, Katoch, Anamika, Horowitz, Nina, Lannin, Donald, Chagpar, Anees, Park, Tristen, Marczyk, Michal, Frederick, Courtney, Burrello, Trisha, Ibrahim, Eiman, Qing, Tao, Bai, Yalai, Blenman, Kim, Rimm, David L., Pusztai, Lajos
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7870853/
https://ncbi.nlm.nih.gov/pubmed/33558513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00219-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi